196 related articles for article (PubMed ID: 36497307)
1. Hepatoblastoma Cancer Stem Cells Express PD-L1, Reveal Plasticity and Can Emerge upon Chemotherapy.
Lee-Theilen M; Fadini DD; Hadhoud JR; van Dongen F; Kroll G; Rolle U; Fiegel HC
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497307
[TBL] [Abstract][Full Text] [Related]
2. Co-Expression of CD34, CD90, OV-6 and Cell-Surface Vimentin Defines Cancer Stem Cells of Hepatoblastoma, Which Are Affected by Hsp90 Inhibitor 17-AAG.
Lee-Theilen M; Hadhoud JR; Volante G; Fadini DD; Eichhorn J; Rolle U; Fiegel HC
Cells; 2021 Sep; 10(10):. PubMed ID: 34685577
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
[TBL] [Abstract][Full Text] [Related]
5. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.
Hsu JM; Xia W; Hsu YH; Chan LC; Yu WH; Cha JH; Chen CT; Liao HW; Kuo CW; Khoo KH; Hsu JL; Li CW; Lim SO; Chang SS; Chen YC; Ren GX; Hung MC
Nat Commun; 2018 May; 9(1):1908. PubMed ID: 29765039
[TBL] [Abstract][Full Text] [Related]
6. Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas.
Gross ETE; Peinado CD; Jung Y; Han S; Liu B; Santosa EK; Bui JD
Oncoimmunology; 2019; 8(1):e1404212. PubMed ID: 30546937
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
8. Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence.
Lopez DC; Fabian KP; Padget MR; Robbins YL; Kowalczyk JT; Lassoued W; Pastor DM; Allen CT; Gallia GL; Gulley JL; Hodge JW; London NR
Front Oncol; 2024; 14():1376622. PubMed ID: 38741774
[TBL] [Abstract][Full Text] [Related]
9. PGE
Lin MC; Chen SY; He PL; Herschman H; Li HJ
Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
[TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A
Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001
[TBL] [Abstract][Full Text] [Related]
11. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
[No Abstract] [Full Text] [Related]
12. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract][Full Text] [Related]
13. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression on Lung Cancer Stem Cells in Metastatic Lymph Nodes Aspirates.
Raniszewska A; Polubiec-Kownacka M; Rutkowska E; Domagala-Kulawik J
Stem Cell Rev Rep; 2019 Apr; 15(2):324-330. PubMed ID: 30397852
[TBL] [Abstract][Full Text] [Related]
15. Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.
Skowron MA; Niegisch G; Fritz G; Arent T; van Roermund JG; Romano A; Albers P; Schulz WA; Hoffmann MJ
J Exp Clin Cancer Res; 2015 Nov; 34():144. PubMed ID: 26606927
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma.
Alisi A; Cho WC; Locatelli F; Fruci D
Int J Mol Sci; 2013 Dec; 14(12):24706-25. PubMed ID: 24351843
[TBL] [Abstract][Full Text] [Related]
17. CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.
Cao L; Bridle KR; Shrestha R; Prithviraj P; Crawford DHG; Jayachandran A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163489
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines.
Wang P; Gao Q; Suo Z; Munthe E; Solberg S; Ma L; Wang M; Westerdaal NA; Kvalheim G; Gaudernack G
PLoS One; 2013; 8(3):e57020. PubMed ID: 23469181
[TBL] [Abstract][Full Text] [Related]
19. Increased PD-L1 expression in breast and colon cancer stem cells.
Wu Y; Chen M; Wu P; Chen C; Xu ZP; Gu W
Clin Exp Pharmacol Physiol; 2017 May; 44(5):602-604. PubMed ID: 28107571
[TBL] [Abstract][Full Text] [Related]
20. UCH-L1 and UCH-L3 regulate the cancer stem cell-like properties through PI3 K/Akt signaling pathway in prostate cancer cells.
Lee JE; Lim YH; Kim JH
Anim Cells Syst (Seoul); 2021; 25(5):312-322. PubMed ID: 34745437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
